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Abstract
Background: About 2–3 % of the population participates in blood donation programmes. Each whole blood donation
or ten apheresis donations cause a loss of 200–250 mg of iron. As a result, one of the most common risks of regular
blood donors is iron deficiency. Although this has been known for decades, in most countries, iron status is currently not
assessed or treated in this population. Premenopausal women are particularly affected, as they have lower iron reserves
and higher daily requirements. Besides anaemia, iron deficiency may lead to fatigue and impaired cognitive and physical
performance. Current iron preparations for intravenous administration are well tolerated and allow for application of large
doses up to 1 g in one visit. Our hypothesis is that in blood donors with iron deficiency, intravenously administered iron
is more efficient and as safe as oral iron supplementation. Since anaemia is one of the most frequent reasons for
permanent or intermittent donor deferral, maintaining an iron-replete donor pool may help to prevent shortages in
blood supply and to avoid iron deficiency-related comorbidities.
Methods/design: In this randomised clinical trial we include male and female blood donors aged ≥18 and ≤65 years
with a ferritin value of ≤30 ng/ml. Stratified by gender, participants are randomized with a web-based randomisation tool
in a 1:1 ratio to either 1 g of intravenously administered ferric carboxymaltose or 10 g of iron fumarate supplements at
one to two daily doses of 100 mg each. Eight to 12 weeks after the first visit, iron status, blood count and symptoms are
assessed in both groups. The primary endpoint is the difference in transferrin saturation (%) following the intervention
between both groups. Secondary endpoints include other parameters of iron metabolism and red blood cell count, the
number of patients with drug-related adverse events, and subjective symptoms including those of the restless legs
syndrome, quality of life, and fatigue.
Discussion: Iron supplementation administered intravenously in non-anaemic but iron-deficient blood donors
could represent an effective strategy to protect blood donors from comorbidities related with iron deficiency
and therefore improve blood donor wellbeing. Furthermore, iron supplementation will help to maintain an
iron-replete blood donor pool.
Trial registration: EudraCT: 2013-000327-14, Clinical Trials Identifier: NCT01787526. Registered on 6 February 2013.
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Background
Iron deficiency is possibly the most prevalent nutritional
deficiency worldwide, but guidelines for its diagnosis and
treatment vary in their suggestions [1, 2]. The largest part
of iron is bound to haemoglobin in red blood cells [1].
Each whole blood donation (plus additional samples for
testing) causes an iron loss of 200 to 300 mg [3]. There-
fore, iron deficiency is prevalent among healthy blood do-
nors, who represent up to 2–3 % of the population [4–10].
Contributing risk factors for iron deficiency include dona-
tion frequency, low body weight, and female gender [6, 8,
9]. Traditionally, safety issues in transfusion medicine have
been concentrating on product quality and patient safety.
However, there is still room for optimizing donor care
[11]. In Austria, the maximal annual donation frequency
for whole blood donations is 4 times for premenopausal
women, 5 times for postmenopausal women and 6 times
for men. The maximal annual donation frequency for
platelet apheresis is 26 times and for plasmapheresis 50
times [12]. Recently, it has been shown that without iron
supplementation, whole blood donors do not recover their
predonation hemoglobin and iron status within 6 months
[13]. Iron depletion in blood donors has been recognized
for decades [14], and anaemia is routinely assessed by
point-of-care haemoglobin devices, but iron status is not.
Therefore, non-anaemic iron-deficient donors may not be
identified, as iron deficiency may lead to subtle and unspe-
cific symptoms [15].
Several trials have evaluated different regimens of iron
supplementation in blood donors and demonstrated good
treatment efficacy in improving iron status [13, 16–24].
However, many iron-deficient blood donors may need to
permanently take oral iron if they continue to donate fre-
quently, since it typically takes 2–3 months to correct iron
deficiency, which is the minimal time interval between
whole blood donations. High-dose iron preparations for
intravenous administration have become available which
allow for the application of a large dose of 1000 mg in one
visit, correcting iron deficiency in many individuals with a
single infusion [25]. To our knowledge, only two interven-
tional trials using high-dose iron intravenous administra-
tion have been performed in blood donors, but only in
one study was iron deficiency required for inclusion
[26, 27]. Currently, intravenous iron is not routinely ac-
cessible to iron-deficient blood donors, and there are no
studies that have compared intravenously administered iron
to oral iron supplements in this setting. In our study, we
aim to establish that intravenous iron is feasible for correc-
tion of iatrogenic iron deficiency in blood donors. When
costs and logistical impediments are overcome, this could
be a one-stop approach if intravenous iron is given immedi-
ately after donation through the available venous access.
The potential risks related to iron therapy include the
masking of other causes of iron deficiency, iron overload
in unrecognized hemochromatosis, and drug-related
adverse effects. Results from interventional trials in
other settings indicate that severe drug reactions of oral
and intravenous iron are rare, and that gastrointestinal
side effects are experienced less often with intravenously
administered iron than with oral iron supplements
[25, 28]. However, anaphylactic reactions have been
described in the intravenous administration of iron [29]. A
novel, frequent adverse effect after the intravenous in-
fusion of iron and more frequently after ferric carboxy-
maltose infusion is hypophosphatemia, which may be
severe and can lead to profound weakness and even
osteomalacia [30–33].
Aims and hypothesis of the study
This study will assess the efficacy, safety, and feasibility
of intravenous infusion of high-dose iron in blood do-
nors with iron deficiency by comparing intravenously
administered ferric carboxymaltose with oral iron fumar-
ate supplements.
Our hypothesis is that 1 g of intravenously infused
ferric carboxymaltose will improve the iron status of
blood donors with iron deficiency more efficiently com-
pared to a comparable dose of oral iron supplements
(10 g assuming a 10 % resorption rate, given over 8–12
weeks).
Methods/design
A SPIRIT checklist is available online for this manuscript
(Additional file 1).
Study design
This is a prospective, randomised, clinical trial. The
study population consists of healthy adults, including
male and female whole blood and platelet apheresis
donors with iron deficiency (ferritin ≤ 30 ng/ml).
Participants
Inclusion criteria
The inclusion criteria are as follows:
 Age ≥ 18 years and ≤ 65 years
 Iron deficiency (ferritin ≤30 ng/ml at screening —
usually before blood donation)
 Fulfilment of the Austrian criteria for blood donation
Exclusion criteria
The exclusion criteria are as follows:
 Known haemochromatosis
 Acute infection
 Pregnancy or lactation
 History of anaphylaxis to intravenous infusion of
iron or other substances
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 Signs or symptoms suggestive of acute or chronic
gastrointestinal or excessive gynaecological bleeding
Study drugs/intervention
The study drugs used in the intervention are:
 High-dose (1000 mg) intravenous infusions of iron
(ferric carboxymaltose, Ferinject ®, manufacturer
Vifor Pharma, Austria) or
 Oral supplements of iron (iron fumarate, Ferretab®,
manufacturer Gerot Lannach, Austria) in a
corresponding estimated dose of >10.000 mg
(assuming an absorption of 10 %, 100 capsules of
152 mg iron fumarate each) taken over 8–12 weeks.
Participants are advised to take tablets in the
morning with orange or lemon juice.
Outcomes
Primary endpoint
 The primary endpoint is the difference in transferrin
saturation (%) at visit 1 between the high-dose
intravenous infusion and the oral iron supplement
group
Secondary objectives
The secondary objectives are:
 Other parameters of iron metabolism, red blood cell
count including the percentage of participants with
a normal (gender-specific) haemoglobin at visit 1 (group
comparison) and further parameters (e.g. phosphate)
 Symptoms including those of restless legs syndrome,
quality of life, fatigue
 Comparison of the two treatments regarding the
incidence and severity of adverse events, tolerance,
and compliance
Methods of procedure
A flow chart of the study procedure is given in Fig. 1.
The total study duration for each patient will be 8–12
weeks. Based on previous experiences in the recruitment
of blood donors for observational studies, we aim to in-
clude two study participants per week. Thus, the total
recruitment period is estimated to last for 21–24 months
and the total active study duration will be 26 months.
Recruitment started in June 2014 and was completed in
June 2016. At the time of revision, all 176 participants
(172 according to the sample size calculation plus 4
dropouts) have been included.
Study duration for the individual participant
The active treatment period for each participant is 8–12
weeks.
Screening
Typically after a regular whole blood or platelet apheresis
donation, ferritin is measured from the remaining serum
for routine infectious disease testing. The regular written
informed consent for blood donation covers the additional
ferritin analysis. Donors with a serum ferritin ≤30 ng/ml
will then be invited by telephone to participate in the study.
Fig. 1 Study flow chart
Macher et al. Trials  (2016) 17:527 Page 3 of 7
Visit 0 including randomization procedure (4–6 weeks
after blood donation)
Donors willing to participate are requested to visit the
Apheresis Unit of the Department of Blood Group Serology
and Transfusion Medicine. After giving written informed
consent, checking inclusion/exclusion criteria and perform-
ing a urine pregnancy test in premenopausal females, a case
report form (CRF) is filled out by the donor.
The CRF includes questions on the following aspects:
– History of blood donation (total number, time)
– History of anaemia
– Symptoms of fatigue
– Subjective physical and cognitive performance
including self-reported physical activity and hours
worked per week
– Symptoms of depression or lethargy
– Trophic changes of fingernails or hair
– Fatigue induced by blood donation
– Symptoms of restless legs syndrome
Randomization procedure
Each participant will be randomized in a 1:1 ratio (stratified
by gender) to either high-dose parenterally infused iron or
oral iron supplements using a web-based randomisation
tool (http://www.randomizer.at). Good clinical practice
(GCP) compliance of this software was confirmed by the
Austrian Agency for Health and Food Safety (AGES).
Blood samples
A blood sample (~30 ml) is drawn from all participants,
in case of randomisation to parenterally infused iron
from a venous access placed for the application of the
intravenously administered iron. Some parameters may
be measured after the end of the study from frozen
blood specimens stored at −70 °C.
Faecal occult blood tests
To assess occult gastrointestinal bleeding, all participants
are asked to perform three faecal occult blood tests at
home in the time between visit 0 and visit 1.
Medication
According to the randomization, either 100 tablets of
oral iron supplements are handed out to the participant
or iron is administered intravenously by the study inves-
tigators in the presence of a nurse.
For oral iron supplements, all participants receive an
exact schedule for tablet intake together with clear in-
structions according to the package leaflet: we suggest to
take 10 tablets per week (3 days 2 tablets, 4 days 1 tablet)
and to take the tablets with orange juice.
Iron is administered intravenously to the participants
in a bed in a separate room of the Apheresis Unit of the
University Clinic of Blood Group Serology and Trans-
fusion Medicine. Iron is infused intravenously over
30 minutes or more over a dedicated peripheral line. A
standard operating procedure involving the resuscitation
outreach team of the Department of Anesthesiology has
been developed, and basic emergency equipment is
available at all times.
Visit 1 (8–12 weeks after visit 0)
A treatment period of 8–12 weeks is chosen because the
administration of 8–13 doses of 100 mg iron in one week
is feasible and it also matches the typical donation
interval. Furthermore, serum ferritin levels are falsely
high when analysed ≤6 weeks after intravenous infusion
of iron.
A CRF including assessment of compliance is completed
by the donor, and a blood sample (~30 ml) is drawn. All
results are summarized in a written report for the study
participants and sent by regular mail.
The CRF at visit 1 will additionally include questions
on the following aspects:
– Information on any relevant adverse events, serious
adverse events and adverse drug reactions
– Compliance with oral study medication intake
(self-reported; the participants are also asked to
bring back all leftover medication)
Statistical aspects
Sample size justification
The sample size calculation was performed by the Depart-
ment of Medical Informatics, Statistics and Documenta-
tion of the Medical University of Graz. Using a two-group
t test with a 0.05 two-sided significance level, a sample size
of 86 participants in each group will have 90 % power to
detect a difference in mean of 8 % in transferrin saturation
(estimating a post-treatment transferrin saturation of 28 %
and 20 % in the high-dose intravenous iron group and oral
iron group, respectively, based on results by a similar
treatment regimen in otherwise healthy women with post-
partum anaemia [34]). Allowing for a dropout of 14 %, ori-
ginally 200 participants were planned to be enrolled in the
study. As the actual dropout rate was substantially lower
(<3 %), the study will be terminated after complete study
participation of 172 participants plus the number of
dropouts.
Statistical procedures
Statistical analyses of the results will be performed using
the intention-to-treat and the per-protocol principles.
All study participants who are randomised and included
into the study will be analysed whether they take their
study medication for the entire term (oral iron) or not
or whether or not they miss the follow-up visit (visit 1).
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All primary and secondary outcome measures will be
analysed and checked for normal distribution of the re-
sults. If there is a normal distribution of laboratory results,
they will be analysed by the two-sided t test; if there is not
a normal distribution they will be analysed by non-
parametric tests like the Wilcoxon test for related samples
or the Mann-Whitney U test for comparison of independ-
ent samples. The significance level will be set to p < 0.05.
Data will be presented as mean ± standard deviation or
median (interquartile ranges) as appropriate. For missing
data, no imputation will be performed. A statistical evalu-
ation will be performed using the software program SPSS
for Windows (IBM SPSS Inc., Chicago, IL, USA).
A predefined subgroup analysis will separately analyse
participants with a baseline ferritin of ≤15 ng/ml. The
Department of Blood Group Serology and Transfusion
Medicine, Medical University of Graz, will maintain re-
sponsibility for the final trial dataset.
Data and safety monitoring
All laboratory analyses are stored on password-protected
secure servers and will only be accessible for authorized
individuals from the Medical University of Graz. Clinical
data are collected through paper-based CRFs. The CRFs
are confidential documents and held securely at the
Department of Blood Group Serology and Transfusion
Medicine. Each participant is assigned a trial identity
code number to anonymize documented CRF data.
In the CRF of the follow-up visit (visit 1), the partici-
pants are asked for possible drug-related adverse events.
Furthermore, all participants are requested to promptly
report possible adverse events by telephone. The study
participants receive telephone contact numbers from the
study team at the time of inclusion (visit 0).
Subject recruitment
In Styria, annually about 60.000 units of whole blood are
collected at mobile and stationary locations by the Red
Cross and further processed to packed red blood cell
concentrates, pooled platelet concentrates and fresh fro-
zen plasma at the Department of Blood Group Serology
and Transfusion Medicine of the Medical University of
Graz. Approximately 1200 single donor platelet apheresis
collections are performed in our department per year. A
number of different commercial plasma collection centres
in the region offer the opportunity to donate apheresis
plasma.
Depending on the region of residence, we estimate
that 5000 to 10,000 donors are potential participants of
this study. Of those, 1000 to 2000 may fulfil the inclu-
sion and exclusion criteria; thus, we need to recruit
10–20 % of all potential participants. We aim to recruit
two blood donors per week for this trial.
The University Hospital of Graz (“LKH-Universitätsk-
linikum Graz”) is a large tertiary care facility with 7200
employees. It is the teaching hospital for one of the three
public Medical Universities in Austria. The catchment
area covers the entire southeast of Austria (approximately
2 million people). Currently 1413 beds at general wards
and 112 intensive care unit (ICU) beds are available.
Each year, approximately 80,000 patients are treated as
inpatients and 440,000 as outpatients.
Specific gender relevance of the project
Adverse reactions related to blood donation are more
common in females, which is one of the major reasons
why more men become regular donors [35]. In particular,
iron deficiency caused by blood donation is highly preva-
lent in premenopausal female donors because of lower
blood volume, higher requirements, and greater losses
during menstrual bleeding, pregnancies, birth, and lacta-
tion [6, 8, 9, 36, 37]. The estimated iron loss from one
whole blood donation corresponds to approximately 10 %
of total body iron and 66–97 % of the total iron stores of a
premenopausal woman [38, 39].
More importantly, unrecognized and therefore untreated
iron deficiency has been linked to adverse pregnancy out-
comes such as preterm delivery and lower weight babies
[40]. Particularly in the subgroup of premenopausal fe-
males, a regular evaluation of donor iron status should be
considered or the donation intervals prolonged.
Study participation for premenopausal women
There are no data available on foetal toxicity of ferric
carboxymaltose, so the application of this drug during
the early stages of pregnancy is contraindicated. There-
fore, women of childbearing age are only allowed to par-
ticipate in this trial when pregnancy has been excluded
by urinary β-HCG testing at the beginning of the study
and is repeated by the participants in the intervention
phase. Lactating women are excluded from blood dona-
tion and therefore are also not targeted in this study.
Ethical aspects
The approval of the institutional ethical committee was
given in June 2013 (EK 25–345 ex 12/13) and has been
renewed yearly.
Registration at clinical trials
This trial was registered at ClinicalTrials.gov in February
2013 (Clinical Trials Identifier: NCT01787526).
Discussion
Iron deficiency anaemia occurs when iron stores have
been consumed [1]. Before establishment of anaemia, iron
deficiency may have other, more subtle and unspecific ad-
verse effects on an individual such as decreased physical
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and cognitive performance [41, 42]. Since iron is an
important element in many enzymes, deficiency may
affect various cellular processes like DNA synthesis [43],
mitochondrial energy metabolism [44], and the immune
system [45]. Therefore, blood donation establishments
should focus on donors at risk for iatrogenic iron defi-
ciency without anaemia and develop strategies for its pre-
vention. Although the benefit of iron therapy in subjects
without anaemia remains controversial, mainly due to a
lack of large randomised clinical trials for truly deficient
subjects, a few studies have reported interesting results.
For example, iron supplementation reduced unexplained
fatigue in otherwise healthy women with iron deficiency
and improved verbal learning and memory in adolescent
girls [15, 46]. Iron deficiency has additionally been found
to be associated with restless legs syndrome, and iron
therapy improved symptoms significantly in blood donors
[47]. Recently, it was shown that the recovery of blood do-
nors’ iron stores receiving oral iron supplementation after
blood donation took a median of 76 days compared to a
median recovery time of longer than 168 days for study
participants not taking iron [13], also questioning the
current relatively short donation intervals of 2–3 months.
So far, no randomised controlled trial has compared
high-dose intravenous iron to oral iron supplementation
in blood donors with iron deficiency. Intravenous iron
may be an excellent option in this setting. If our study
can establish that intravenous iron is feasible in blood
donors and the substantial impediments like costs and lo-
gistics can be overcome, high-dose intravenously infused
iron given immediately after whole blood or apheresis do-
nation through the present venous access could be a very
efficient way for correction and/or prevention of iatro-
genic iron deficiency. Such an approach could protect
blood donors from symptoms related to iron deficiency
and help to maintain an iron-replete blood donor pool.
Trial status at the time of initial manuscript submission
Recruitment for this trial is ongoing.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*. (DOCX 63 kb)
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